Does the Pfizer mRNA COVID-19 Vaccine Cause Blood Clots?
The Pfizer-BioNTech mRNA COVID-19 vaccine does not cause blood clots and is not associated with the rare vaccine-induced immune thrombotic thrombocytopenia (VITT) syndrome seen with adenoviral vector vaccines. 1
Key Evidence from Clinical Trials and FDA Data
The FDA drug label data for mRNA vaccines (including Pfizer-BioNTech) explicitly states: "There were no notable patterns or imbalances between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship" to the vaccine. 1
In clinical trials involving over 30,000 participants, no increased risk of thrombotic events was observed in vaccine recipients compared to placebo groups across all age ranges studied (6 years through adults). 1
Among adolescents (12-17 years), with median follow-up of 312 days, there were no patterns suggesting causality between vaccination and thrombotic events. 1
VITT: A Distinct Entity Not Associated with mRNA Vaccines
VITT is specifically caused by adenoviral vector COVID-19 vaccines (like AstraZeneca/ChAdOx1-S), not mRNA vaccines like Pfizer-BioNTech. 2
VITT occurs due to anti-platelet factor 4 (PF4) antibodies that develop 5-30 days after adenoviral vector vaccination, causing intense platelet activation and thrombosis. 2
The incidence of VITT is 14.9 per million after first dose of adenoviral vaccines, but this complication has not been linked to mRNA vaccines. 2
Supporting Research Evidence
Multiple high-quality studies confirm the absence of thrombotic risk with Pfizer-BioNTech:
A 2023 New Zealand self-controlled case series of 6,039 hospitalized thrombosis patients found no increased risk of venous thromboembolism (IRR 0.87,95% CI: 0.76-1.00), arterial thrombosis (IRR 0.73,95% CI: 0.56-0.95), or cerebral venous thrombosis after BNT162b2 vaccination. 3
A 2023 study of 567 healthcare workers found no increase in thrombin generation, D-dimer levels, or coagulation activation after mRNA vaccination (including Pfizer-BioNTech), and no participants developed thrombosis or VITT. 4
A 2023 head-to-head comparison of four COVID-19 vaccines (including Pfizer-BioNTech) showed no platelet activation or microvesicle release, and no anti-PF4 seroconversion after vaccination. 5
A 2021 analysis of US vaccine adverse event data in women ≤50 years (a high-risk group for hormonal contraceptive-related thrombosis) found only 1 case per 222,951 vaccinated with Pfizer or Moderna, with no disproportional reporting of thromboembolic events compared to hormonal contraceptive use. 6
Important Clinical Context
The risk-benefit analysis strongly favors vaccination: A 2024 study found that while there may be a minimal transient increase in blood clot risk immediately post-vaccination (IRR 1.13-1.23), vaccination substantially reduces the much larger risk of blood clots from COVID-19 infection itself (OR 2.16 in unvaccinated vs 1.46 in vaccinated). 7
Rare Case Reports Require Context
Isolated case reports of lupus anticoagulant-associated thrombosis after Pfizer vaccination exist, but these are extremely rare and lack the thrombocytopenia characteristic of VITT. 8
A 2025 systematic review identified hematologic disorders post-vaccination, but most outcomes were favorable (77%), and these represent exceedingly rare events given billions of doses administered. 9
When thrombotic events occur temporally near vaccination, detailed analysis is required to distinguish coincidental occurrence from causation, as VTE affects 1-2 per 1,000 persons annually regardless of vaccination. 10